Alluvi Tirzepatide 40mg
The dual GIP/GLP-1 agonist that set a new benchmark for metabolic peptide research. Alluvi Healthcare’s Tirzepatide 40mg vial supplies it in lyophilized form — stable, documented, and suited to controlled laboratory studies.
Oxford Peptide Innovations stocks this directly from Alluvi Healthcare, verified and batch-traceable.
Alluvi Tirzepatide 40mg: Where It Fits in Current Research
When published Phase 3 data reported average weight reductions of 20–22% at 72 weeks, Tirzepatide fundamentally shifted expectations for what metabolic research compounds could achieve. Its dual-agonist mechanism — GIP and GLP-1 receptor activity simultaneously — showed that moving beyond single-pathway targeting produced meaningfully better outcomes in trial settings.
That mechanistic lesson is part of what drove research interest in Retatrutide’s triple-agonist approach. For labs running comparative studies, having Tirzepatide and Retatrutide available from verified sources is essential to study design integrity.
Each Alluvi Tirzepatide 40mg vial is:
- Manufactured by Alluvi Healthcare to high-purity standards
- Supplied as a lyophilized powder for stability
- Batch-tested and sealed before dispatch
- Supplied with full traceability documentation
- For research and development use only
Tirzepatide and Retatrutide — Stocking Both
Researchers comparing Tirzepatide and Retatrutide across receptor pathways can source both through Oxford Peptide Innovations:
- Alluvi Retatrutide 40mg Pen — higher-strength pen format
- Synedica Tirzepatide 40mg Pen — alternative manufacturer pen format
For published comparative research context:
Provided for scientific context only. Not medical advice.
Storage
- Refrigerate at 2–8°C or freeze for long-term storage
- Keep away from direct light and moisture
- Sterile reconstitution technique required
- Follow standard peptide-handling protocols after reconstitution
Research Use Only
This product is sold strictly for laboratory R&D. Not for human or animal consumption. Not a medicine or supplement. Not MHRA or FDA evaluated for therapeutic use. For qualified researchers only. Purchasers must be 18+.
Related Products
- Synedica Tirzepatide 40mg Pen
- Alluvi Retatrutide 20mg
- Alluvi Retatrutide 40mg Pen
- Alluvi NAD+ 1,000mg
- Full Peptide Range
FAQ
Is Alluvi Tirzepatide 40mg available in the UK? Yes — stocked and dispatched by Oxford Peptide Innovations from within the UK.
Is there a pen format for Tirzepatide? Yes — see our Synedica Tirzepatide 40mg pen.
Is this suitable for human use? No. R&D use only.
Related products
ALLUVI
ALLUVI
ALLUVI
ALLUVI